Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging

Cancer Nanotechnology

Volumn 1, Issue 1-6, 2010, Pages 71-78

  Jin, Honglin ^a,b,c   Lovell, Jonathan F ^a,d   Chen, Juan ^a   Ng, Kenneth ^a,d   Cao, Weiguo ^a,b   Ding, Lili ^a   Zhang, Zhihong ^c   Zheng, Gang ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

EGF; GFP; Lung cancer; Nanoparticles; Targeting specificity

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTORCONJUGATED HIGH DENSITY LIPOPROTEIN MIMICKING PEPTIDE PHOSPHOLIPID SCAFFOLD; GREEN FLUORESCENT PROTEIN; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL LABELING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INTERNALIZATION; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 79952700412     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-010-0009-x     Document Type: Article

References (23)

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Sci NY NY 271(5248):518-520
2. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56(11):1649-1659
3. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54(5):631-651
4. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615-1626
5. Chen H, Wang L, Yeh J, Wu X, Cao Z, Wang YA, Zhang M, Yang L, Mao H (2010) Reducing non-specific binding and uptake of nano- particles and improving cell targeting with an antifouling PEO-b- PgammaMPS copolymer coating. Biomaterials 31(20):5397-5407
6. Corbin I, Chen J, Cao W, Lin H, Lund-Katz S, Zheng G (2007) Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers. J Biomed Nanotechnol 3(4):367-376
7. Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, Valerius T (2007) Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 179(5):2936-2943
8. Doroshow JH (2005) Targeting EGFR in non-small-cell lung cancer. N Engl J Med 353(2):200-202
9. Gatzemeier U (2003) Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. Oncol Williston Park NY 17(11 Suppl 12):7-10
10. Jiang W, Kim BY, Rutka JT, Chan WC (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3):145-150
11. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nano- medicines: principles and practice. Br J Cancer 99(3):392-397
12. Nakamura T, Takasugi H, Aizawa T, Yoshida M, Mizuguchi M, Mori Y, Shinoda H, Hayakawa Y, Kawano K (2005) Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. J Biotechnol 116(3):211-219
13. Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Reviews 9(8):615-627
14. Poste G, Tzeng J, Doll J, Greig R, Rieman D, Zeidman I (1982) Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci USA 79 (21):6574-6578
15. Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, Hendler A, Vallis K, Gariepy J (2000) A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 41(5):903-911
16. Senekowitsch-Schmidtke R, Steiner K, Haunschild J, Mollenstadt S, Truckenbrodt R (1996) In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425. Cancer Immunol Immunother 42(2):108-114
17. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, Hodik M, Stahl S, Frejd FY, Orlova A (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50(2):274-283
18. Vincent A, Babu S, Heckert E, Dowding J, Hirst SM, Inerbaev TM, Self WT, Reilly CM, Masunov AE, Rahman TS, Seal S (2009) Protonated nanoparticle surface governing ligand tethering and cellular targeting. ACS Nano 3(5):1203-1211
19. Wool GD, Reardon CA, Getz GS (2008) Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti- atherogenic properties. J Lipid Res 49(6):1268-1283
20. Yu DH, Lu Q, Xie J, Fang C, Chen HZ (2010) Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31(8):2278-2292
21. Zhang Z, Cao W, Jin H, Lovell JF, Yang M, Ding L, Chen J, Corbin I, Luo Q, Zheng G (2009) Angew Chem Int 48(48):9171-9175
22. Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G (2010) HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small Weinheim Bergstrasse Ger 6(3):430-437
23. Zheng G, Chen J, Li H, Glickson JD (2005) Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 102(49):17757-17762